Abstract #4036

Probing white matter abnormalities in preclinical and early Alzheimer’s disease

Qing Wang^1,2, Yong Wang^1,3,4, Joshua S Shimony¹, Anne M Fagan^2,5, John C Morris^5,6, and Tammie L.S. Benzinger^1,6,7

¹Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, United States, ²Knight Alzheimer's Disease Research Center, St. Louis, MO, United States, ³Obstetrics and Gynecology, Washington University in St. Louis, St. Louis, MO, United States, ⁴Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, United States, ⁵Neurology, Washington University in St. Louis, St. Louis, MO, United States, ⁶Knight Alzheimer’s Disease Research Center, St. Louis, MO, United States, ⁷Neurosurgery, Washington University in St. Louis, St. Louis, MO, United States

Robust neuroimaging biomarker sensitive to the early white matter abnormalities could provide novel insights into the pathogenesis of Alzheimer’s disease (AD), and serve as surrogate measures for disease progression. We demonstrated that novel DBSI white matter abnormality biomarkers strongly correlate with invasive CSF measures of neuronal injuries, and provide specific preclinical measures of WM abnormalities for early diagnostics and accurate assessment of disease-modifying therapies targeting neuro-protection in AD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here